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Background: Through many years, the standard care has been to use continuous sedation of critically ill patients
during mechanical ventilation. However, preliminary randomised clinical trials indicate that it is beneficial to reduce
the sedation level. No randomised trial has been conducted comparing sedation with no sedation, a priori powered
to have all-cause mortality as primary outcome.
The objective is to assess the benefits and harms of non-sedation versus sedation with a daily wake-up trial in
critically ill patients.
Methods/Design: The non-sedation (NONSEDA) trial is an investigator-initiated, randomised, clinical, parallel-group,
multinational trial designed to include 700 patients from at least six ICUs in Denmark, Norway and Sweden.
Inclusion criteria are mechanically ventilated patients with expected duration of mechanical ventilation >24 hours.
Exclusion criteria are non-intubated patients, patients with severe head trauma, coma at admission or status
epilepticus, patients treated with therapeutic hypothermia, patients with PaO2/FiO2 < 9 where sedation might be
necessary to ensure sufficient oxygenation or place the patient in prone position.
Experimental intervention is non-sedation supplemented with pain management during mechanical ventilation.
Control intervention is sedation with a daily wake-up trial.
The primary outcome will be all cause mortality at 90 days after randomization. Secondary outcomes will be: days
until death throughout the total observation period; coma- and delirium-free days; highest RIFLE score; days until
discharge from the intensive care unit (within 28 days); days until the participant is without mechanical ventilation
(within 28 days); and proportion of patients with a major cardiovascular outcome. Explorative outcomes will be: all
cause mortality at 28 days after randomisation; days until discharge from the intensive care unit; days until the
participant is without mechanical ventilation; days until discharge from the hospital; organ failure.
Trial size: we will include 700 participants (2 × 350) in order to detect or reject 25% relative risk reduction in
mortality with a type I error risk of 5% and a type II error risk of 20% (power at 80%).
Discussion: The trial investigates potential benefits of non-sedation. This might have large impact on the future
treatment of mechanically ventilated critically ill patients.
Trial register: ClinicalTrials.gov NCT0196768, 09.01.2014.
Keywords: Critically ill patients, Non-sedation, Daily wake-up trial, Mechanical ventilation, Acute kidney injury,
Delirium, Randomised controlled trial* Correspondence: Palle.Toft@rsyd.dk
1Department Anaesthesiology and Intensive Care, Odense University
Hospital, Sdr. Boulevard 29, DK - 5000 Odense C, Denmark
Full list of author information is available at the end of the article
© 2014 Toft et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Toft et al. Trials 2014, 15:499 Page 2 of 11
http://www.trialsjournal.com/content/15/1/499Background
Patient population
In Denmark approximately 30,000 patients (2 to 3% of
all hospital patients) are admitted to intensive care units
(ICUs) every year. Since treatment in ICUs is highly spe-
cialised and depends on technical equipment, like venti-
lators, it is costly and accounts for a large percentage of
the total hospital expenditure. In 2011, 43% of the pa-
tients in Danish ICUs were medical patients, the rest
surgical patients. The majority of the surgical patients
were hospitalised acute. Mortality during the stay in ICU
was 12.7% and 30-day mortality 21.2% [1]. An intensive
care admission can have substantial consequences for pa-
tients and studies show that ICU survivors have a de-
creased quality of life and an increased mortality for years
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Figure 1 CONSORT flowchart illustrating the randomization and flowCurrent care and treatment
Since the dawn of ventilator therapy, it has been stand-
ard care to sedate the patients continuously. The first
ventilators were rather primitive and highly uncomfort-
able for the patients, making the sedation practice neces-
sary. Though ventilators are now advanced and allow for
better patient-ventilator interaction, the routine of con-
tinuous sedation is still widespread. Continuous sedation
has a reputation of being unavoidable for patients to toler-
ate the ICU environment, the necessary procedures and
so forth. A study from USA in 1991 showed that almost
all patients on ventilators were sedated, some by intermit-
tent administration, while 62% received continuous intra-
venous sedative infusion [3]. A study from Scandinavia in
2004 showed that only 15% of the ICUs who answered the
questionnaire applied daily awakening of the sedatedtion
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scale to monitor sedation depth. A study from Denmark
in 1999 showed that sedatives were used extensively in
Danish ICUs [5].
It has been shown that the level of melatonin in the
blood, which is closely related to a proper diurnal sleep
rhythm, is disturbed in sedated, mechanically ventilated
patients [6]. This disturbed melatonin rhythm could play a
role in the development of delirium, which is common in
critically ill patients, with a prevalence of up to 80% [7].
During the last two decades, several randomised clin-
ical trials have been conducted in an attempt to deter-
mine the adverse effects of continuous sedation during
mechanical ventilation and to reduce the level of sedation
in critically ill patients. The outcomes have primarily been
‘days on mechanical ventilation’ and ‘length of stay’ in
ICU and in hospital. Brook et al. published a randomised
clinical trial, which indicated that the use of protocol-
controlled sedation could reduce the duration of mechan-
ical ventilation, the length of stay in the ICU, and the
number of tracheostomies performed [8].
In 1998, Kollef et al. performed a non-randomised co-
hort study, which showed that continuous intravenous
infusion of sedatives was associated with significantly lon-
ger mechanical ventilation, increased length of stay in the
ICU and in hospital, compared with patients receiving
only bolus doses of sedatives [9]. In 2004, De Jonghe et al.
showed that the use of a sedation algorithm, based on a
regular assessments of the level of consciousness and an
attempt to help the critically ill patients tolerate the inten-
sive care environment, resulted in a significantly shorter
duration of mechanical ventilation, using a historical con-
trol group [10].
In a trial from 2000, Kress et al. randomised 128
critically ill patients receiving mechanical ventilation to
continuous intravenous sedation with or without a daily
wake-up trial, in which the infusion of sedatives was dis-
continued [11]. When it had been ensured that the pa-
tient was co-operable and awake, the patient was put
back to sleep using the continuous intravenous sedation.
The trial showed that the group of patients who were
awakened daily had a significantly shorter stay in the ICU
and a significantly shorter duration of mechanical ventila-
tion. Also, fewer diagnostic computed tomography (CT)
scans of the cerebrum were performed in patients who
were awakened daily [11]. Since Kress et al.’s trial it has
been the golden standard to awaken patients on a daily
basis if continuous intravenous sedation is used.
In 2005, Arroliga et al. carried out a prospective, multi-
centre, cohort study with 5,183 adult patients who were
mechanically ventilated [12]. In this non-randomised
study, it was observed that the use of sedatives for crit-
ically ill, mechanically ventilated patients was associated
with longer duration of mechanical ventilation, a longerweaning period, and a longer stay in the ICU. It was
concluded that randomised clinical trials specifically de-
signed to evaluate the effect of sedation compared with
no sedation should be performed on critically ill, mech-
anically ventilated patients to shed light on this import-
ant issue.
Most critically ill, mechanically ventilated patients in
ICUs throughout the world are still routinely sedated. In
the department of Anaesthesiology and Intensive Care at
Odense University Hospital, we have had a non-sedation
policy during the last decade. We use appropriate analge-
sics as intravenous bolus doses, but we do not sedate the
patients. We undertook a randomised clinical trial to as-
sess if this policy was in fact to the benefit of the patients
[13]. One hundred and forty patients on mechanical venti-
lation were included and randomised to either the current
golden standard of continuous sedation with a daily wake-
up trial or to our standard therapy with no sedation. We
were able to show that the non-sedated group had a sig-
nificantly shorter time on mechanical ventilation (four
days), a significantly shorter stay in the ICU (nine days),
and a significantly shorter stay in hospital (24 days). The
mortality was 22% in the non-sedated group and 38% in
the sedated group (P = 0.06). A post hoc analysis demon-
strated that the rate of acute renal failure was significantly
lower in the non-sedated group [14]. A neuropsychologist
examined a smaller cohort of the surviving patients. This
psychological study demonstrated that the rate of post-
traumatic stress was not significantly higher among pa-
tients who had been awake compared to those who were
treated with the standard strategy of sedation [15].
To identify other randomised clinical trials assessing
the effects of sedation versus non-sedation in mechanically
ventilated, critically ill patients, we undertook a systematic
literature search. We searched the following databases
from inception to October 2013: Medline, Embase, Cinahl
and the Cochrane Library, Central. Only one randomised
clinical trial of sedation versus non-sedation was identi-
fied, namely the one we performed in Odense University
Hospital [13].
The results from our previous trial showed that non-
sedation in critically ill, mechanically ventilated patients
might have substantial beneficial effects [13]. Our object-
ive is now twofold: (1) to examine whether it is possible to
implement non-sedation in other ICUs, and (2) to assess
the clinical effects of non-sedation more thoroughly,
randomising a sufficient number of patients to reach




We will obtain informed consent from the patients who
are sufficiently awake; otherwise the informed consent
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patient’s general practitioner, alternatively the Medical
Health Office.
The trial is approved by the Data Protection Agency
(#2008-58-0035, approval for the Region of Southern
Denmark) and the regional ethics committee (Region
Southern Denmark).
Trial objectives and hypotheses
Objectives
The objective will be to assess the benefits and harms of
the current golden standard of treatment, where mechan-
ically ventilated ICU patients will be continuously sedated
and awakened daily, compared with a strategy with non-
sedation.
Hypotheses
The primary hypothesis is that non-sedation compared
to sedation and a daily wake-up trial will:
 Reduce mortality.
The secondary hypotheses are that non-sedation com-
pared to sedation and a daily wake-up trial will:
 Reduce the incidence of a composite outcome of
death, acute myocardial infarction (AMI), stroke,
pulmonary embolism and other thromboembolic
events.
 Reduce the number of organ failures.
 Increase the days alive without mechanical
ventilation.
 Increase the days alive outside the ICU.
 Increase the days alive outside the hospital.
Trial design
The non-sedation (NONSEDA) trial is an investigator-
initiated, randomised, clinical, parallel-group, multinational,
superiority trial designed to include 700 patients from
at least six ICUs in Denmark, Norway and Sweden
(Additional files 1 and 2).
Randomisation
Patients will be randomised to one of the two groups
within 24 hours after intubation. If the patient arrives
intubated from another ICU, the patient will be rando-
mised within the first 24 hours after arrival. The partici-
pating doctors and study nurses will screen their ICU on
a daily basis. The randomisation will be carried out cen-
trally by the Copenhagen Trial Unit (CTU) according to
a computer-generated allocation sequence with a vari-
able block size, kept concealed from investigators at the
clinical sites.The allocation sequence will be stratified by centre,
age (up to 65 years or older) and shock at admission
(systolic blood pressure <70 mmHg or above).
The randomization system will be internet-based with
24 hours access a day, seven days a week. The participant
allocation will be carried out by an investigator who logs
in to the CTU’s online randomisation system using a per-
sonal ID and PIN code. Then the investigator will type in
all relevant information about the participant, and the par-
ticipant will be subsequently allocated to either the ‘non-
sedation group’ or the ‘sedation group’.
Blinding
Due to the nature of the trial interventions, it will not be
possible to blind the investigators at clinical trial sites,
the participants, and the participants’ relatives. All other
parties in the trial will be blinded. Data regarding out-
comes will be collected from national registers. The stat-
istical analyses will be conducted blinded with the two
intervention groups coded as, for example, A and B. Two
conclusions will be drawn by the blinded steering commit-
tee; one assuming A is the experimental group and B in
the control group, and one assuming the opposite. After
that the code will be broken.
Selection of participants
Patients will be included in the NONSEDA trial if
they comply with the following inclusion and exclu-
sion criteria:
Inclusion criteria
 Endotracheally intubated within the last 24 hours
 Expected time on ventilator >24 hours as estimated
by the attending physician
 Age ≥18 years
 Informed consent
Exclusion criteria
 Severe head trauma where therapeutic coma is
indicated
 Therapeutic hypothermia where therapeutic coma is
indicated
 Status epilepticus where therapeutic coma is
indicated
 Patient has participated in the study before
 Patient is transferred from another ICU with length
of stay >48 hours
 Patient is comatose at admission
 Patient is brain dead
 The ratio of partial pressure arterial oxygen and
fraction of inspired oxygen (PaO2/FiO2) ≤9,
if sedation is necessary for oxygenation or
prone position
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Discontinuation and withdrawal at the choice of the
participant or relative
A participant or a patient’s relative who no longer agrees
to participate in the trial, can withdraw the informed
consent at any time without need of further explanation.
This will not have any consequences for the participant’s
further treatment. In order to conduct intention-to-treat
analyses with as little missing data as possible, it is in the
interest of the trial to collect as much data from each par-
ticipant as possible. Therefore, if possible, the investigator
may ask the participant and/or relatives which aspects of
the trial he/she wishes to withdraw from:
 receiving the trial intervention;
 participation in the remaining follow-up assessments
(questionnaires and physical data);
 collection of data from registers;
 use of already collected data in the data analyses.
In Scandinavia, we have centrally registered the out-
come of all patients. The only loss to follow-up will be pa-
tients who wish to withdraw their informed consent. Thus
patients who, despite randomisation to non-sedation, do
not receive the experimental intervention, is recorded as
intention to treat. Their stay in the ICU will still be care-
fully recorded so that it subsequently will be possible to
characterize the patients who poorly tolerate being awake.
Specifically, it is recorded if failure of non-sedation is re-
lated to agitated delirium, oxygenation problems, or an
unstable circulation. There will be no cross-over between
the groups. If a patient in the non-sedated group needs
sedation a daily wake-up trial will be performed. During
this wake-up trial, it is evaluated if the patient again can
tolerate non-sedation.
We expect that 15 to 20% of the patients in the non-
sedated group will have difficulties tolerating the non-
sedation strategy, mostly because of agitated delirium
(18% discontinued the non-sedation in the previous
study conducted at Odense University Hospital [13]).Selection of trial sites and personnel
Trial sites and setting
Odense University Hospital. Mixed ICU, medical and
surgical patients, 26 beds
Lillebaelt Hospital, Kolding. Mixed ICU, medical and
surgical patients, 11 beds.
Svendborg Hospital. Mixed ICU, medical and surgical
patients, 7 beds.
Esbjerg Hospital. Mixed ICU, medical and surgical pa-
tients, 12 beds.
Aarhus University Hospital, Norrebrogade. Mixed ICU,
medical and surgical patients, 14 beds.Vestfold Hospital, Tønsberg. Mixed ICU, medical and
surgical patients, 6 beds.
Tromsø University Hospital. Mixed ICU, medical and
surgical patients, 10 beds.
Hallands Hospital, Halmstad. Mixed ICU, medical and
surgical patients, 8 beds (Additional file 3).
Trial personnel
The trial personnel will be doctors and nurses in the
selected ICUs. The personnel will be trained in non-
sedation and daily wake-up trials, both in theory and by
supervised practice.
Trial interventions
Experimental intervention - non-sedation
The experimental group will not receive sedatives. Pa-
tients are thoroughly and repeatedly informed by the staff
of where they are, what has happened, and what type of
treatment they are going to receive.
If patients arrive at the ICU sedated and are randomised
to the non-sedation group, the intravenous infusion of
sedatives will be discontinued and the patient will be
awakened.
Participants will be awake and have a natural sleep
rhythm. In case these patients develop an agitated delir-
ium, it is necessary to have a nurse or other caregiver at
the bedside in order to calm the patient. Patients with
delirium will be treated with haloperidol according to
the U.S. guidelines, 2002 and the Danish national guide-
lines [16,17].
If, despite these measures, it is necessary to sedate an
agitated patient more than twice, or where sedation
might be necessary to ensure sufficient oxygenation or
to place the patient in a prone position, the patient will
be sedated. Every day during the wake-up trial it is evalu-
ated whether the patient is able to continue the non-
sedation. There will be no cross-over between the groups.
In the previous trial from Odense, less than 18% of the
included participants experienced failure of non-sedation
(defined as sedation more than twice) [13].
Control intervention - sedation with daily awakening
attempt
The control group will be sedated with continuous infu-
sion of sedatives to Ramsay score 3 to 4. The first 48
hours the patients will be sedated with propofol, after 48
hours midazolam will be used. This is in accordance
with Danish and international practice and guidelines
[16,17]. During the daytime, the patient will be awak-
ened as the intravenous infusion of sedatives will be dis-
continued. The patient will be considered to be awake
when he/she can perform at least three of the following
four tasks:
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 Follow the examiner's instructions with the eyes.
 Squeeze hands on request.
 Stick out the tongue on request.
After a successful wake-up, the infusion of sedative
will be resumed, starting on half of the pre-wake-up
dose. If the patient becomes uncomfortable or agitated
during the awakening, sedation will be resumed, again
starting with half the dosage. The infusion of sedatives
will then be adjusted to Ramsey score 3 to 4.
Time zero is when the randomization is done.Co-interventions
Both intervention groups will receive analgesic treatment
as usual, with opiates and paracetamol, in order to keep pa-
tients comfortable. In case the patient arrives at the depart-
ment with an epidural catheter, the analgesia will continue
via the epidural catheter as usual. The Visual Analogue
Pain score (VAS) will be used to monitor the need for
supplemental analgesics and morphine will be given if
VAS is ≥3 at rest and ≥5 during activity.
All patients will be assessed for delirium on a daily basis,
using the confusion assessment method in the ICU (CAM-
ICU) score. If patients become agitated or delirious, they
will be treated with haloperidol according to national [16]
and international guidelines [17].
We have defined three co-interventions that will be
registered and presented for each intervention group:
 Use of vasoactive agents
 Use of antibiotics
 Total amount of intravenous fluids (including blood
products)
 Total amount of morphine and haloperidolWeaning from the ventilator
During the daily ward rounds it is estimated whether the
patient meets the criteria to start weaning from the venti-
lator. As early as possible, the ventilator will be switched
to pressure support ventilation. The pressure support will
be reduced as much as possible guided daily by pCO2,
tidal volume, and respiratory frequency.
If there are no signs of respiratory acidosis, a daily
weaning trial will be performed. The pressure support
will be reduced with 2 cm of water per hour. In the
sedation group, the weaning trial will take place simul-
taneously with the wake-up trial. The patients will be
awakened if the patient tolerates a weaning trial lasting
30 to 120 minutes without any signs of fatigue (signs of fa-
tigue are shown as a respiratory rate >35, decreasing tidal
volume, respiratory rate divided by tidal volume >105/
minute, rising end tidal CO2 (ETCO2), saturation <90,paradoxical respiration, heart rate >140, systolic blood
pressure >180 or <90).
Sedation will be discontinued when positive end-
expiratory pressure (PEEP) = 5 and FiO2 = 40%.
The patient will be extubated and discharged from the
ICU according to the departments’ clinical criteria.
Guidelines for extubation:
 Pressure Support (PS) <2
 PEEP <5
 FiO2 < 0.4
 Respiration frequency <35
 No CO2 retention
 Heart rate <140
 Adequate secretion quantity/acceptable cough force
Waking the patient
If sedation duration is less than five days, the intravenous
sedation will be discontinued immediately. If the intraven-
ous sedation has lasted more than five days, it must be re-
duced gradually to avoid withdrawal symptoms. Eventually,
sedatives with a long half-life can be exchanged with those
with a short half-life in the hours before the patient is
awakened. Possibly symptoms of withdrawal will be treated
with clonidine.
Compliance
Non-compliance to the protocol will be considered in
the control group if drugs other than propofol and mid-
azolam are used for sedation, if no wake-up trial is
performed and if there is a major deviation from the
Ramsey score 3 to 4.
Non-compliance to the protocol will be considered in
the non-sedation group if the patients are sedated due to
reasons other than agitated delirium, problems with the
oxygenation or the need for the prone position.
The sponsor of the trial and the assigned postdoc will
inspect the participating sites to ensure that the protocol
is followed.
Outcomes
The primary outcome will be:
 All-cause mortality at 90 days after randomisation.
Secondary outcomes will be:
 Days until death throughout the total observation
period.
 Proportion of patients with a major cardiovascular
outcome (acute myocardial infarction, cerebral
infarction, cerebral haemorrhage, pulmonary embolus,
deep vein thrombosis, other thromboembolic event)
at 90 days after randomisation.
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Richmond agitation-sedation scale (RASS) ≥3 and
no positive CAM-ICU scorings the particular day)
within 28 days from randomisation
 Highest Risk, Injury, Failure, Loss of kidney
function, and End-Stage kidney disease (RIFLE)
score within 28 days from randomization
(RIFLE categories [18,19]:
RIFLE-R: increase in serum creatinine × 1.5 from
baseline OR urine output <0.5 mL/kg/hr × 6 h.
RIFLE-I: increase in serum creatinine × 2 from baseline
OR urine output <0.5 mL/kg/hr × 12 h.
RIFLE-F: increase in serum creatinine × 3 from baseline
OR urine output <0.3 mL/kg/hr × 24 h OR creatinine
≥350 μmol/L with acute rise ≥44 μmol/L in <24 h).
 Length of ICU stay, up to death or up to 28 days
post randomization, whatever happens first
 Days until the participant is without mechanical
ventilation (within 28 days from randomisation).
Exploratory outcomes are:
 All-cause mortality at 28 days after randomisation.
 Length of ICU stay, up to death or up to 90 days
post randomization, whatever happens first.
 Days until the participant is without mechanical
ventilation (within 90 days from randomisation).
 Length of hospital stay (within 90 days from
randomisation).
 Organ failure when the patient is discharged from
the ICU.
 Number of accidental extubations requiring re-
intubation within 1 hour
 Number of accidental removals of central venous
lines, requiring re-insertion within 4 hours




Adverse event (AE): any undesirable medical event
occurring to a participant during a clinical trial, which
does not necessarily have a causal relationship with the
intervention [20].
Serious adverse event (SAE): any adverse event
that results in death, is life-threatening, requires
hospitalisation or prolongation of existing
hospitalisation, results in persistent or significantdisability or incapacity, or is a congenital anomaly
or birth defect [20].
Suspected unexpected serious adverse reaction
(SUSAR): any suspected adverse reaction that is both
serious and unexpected (unexpected means that the
nature or severity of the event is not consistent with
the information available to date) [20].
Risks and safety issues in the NONSEDA trial
At the single-centre study at Odense University Hospital,
the ICU diagnosed several patients with agitated delirium
in the non-sedated group [13]. This difference might be
caused by the fact that it is easy to discover agitated delir-
ium in an awake patient. It is very difficult, if not impos-
sible, to diagnose the same condition in a sedated patient.
In this multicentre trial, we will examine all patients
for silent as well as agitated delirium by the use of
CAM-ICU [16].
The sedated group will be awakened daily according to
the Danish and international golden standard. It will
thus be ensured, in both groups, that the participants
will not be unduly heavily sedated with consequent pro-
longed admission.
Recording and reporting of SAEs
As both the primary and the secondary outcomes all
represent a range of possible SAEs, SAEs are estimated
to occur very frequently in almost all patients. There-
fore, only SAEs that are related to the study intervention
will be recorded. These events will be accidental extuba-
tions requiring re-intubation within one hour, and acci-
dental discontinuations of central venous accesses, which
require reinsertion within four hours.
Investigators will report SAEs according to national
standard operational procedures. Participating doctors and
study nurses will screen for AEs. Screening is mandatory.
SAEs will be registered in the electronic case record form
(eCRF) and reported to the Data Monitoring and Safety
Committee (DSMC) and Ethics Committee. The attending
physician decides if an AE is serious.
Procedures, assessments and data collection
Ethics
The study was approved by the Danish Ethics committee
09012014 (ID:S-20130025) and by the Norwegian Ethics
committee 07052014 (ID :2013/2347/REK sor-ost).
Inclusion of patients
Patients can be admitted to the ICU either from the
same hospital (emergency department or another ward)
or transferred from an ICU in another hospital. If they
are admitted from within the same hospital, they are
either not intubated or have been intubated within a
very short time, for example during pre-hospital care.
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post intubation.
Patients transferred from an ICU in another hospital
are very often intubated. If they are transferred from an-
other ICU, they can be included in the trial if the stay in
the other ICU was shorter than 48 hours. In the time
leading up to inclusion and randomisation, it will vary
whether patients are sedated or not, depending on the
particular clinician on duty and traditions at the particu-
lar hospital.
Obtaining informed consent
When patients are contacted the first time concerning
participation in the study, they will be at the ICU. Verbal
and written information will be given by one of the par-
ticipating physicians or study nurses. Patients are in-
formed about the rights to assistance and the possibility
of reflection time.
Patients will be considered competent if they are
awake and not delirious (negative CAM-ICU). The com-
petent patients will give consent after a period of reflec-
tion time of up to several hours.
If patients are not awake and not competent because
of their illness, surrogate consent will be obtained fromTable 1 Data registration time points




APACHE II, SOFA, SAPS II x
Organ effects X
CT- +MR cerebrum X
Unintended discontinuation of equipment X
The use of sedatives X
The use of morphine X
The time on mechanical ventilation
Ventilator-associated pneumonia
Length of stay, ICU
Coma-free, delirium-free days
Death in ICU





Death at 90 days
Serious adverse events X
ICU, intensive care unit; APACHE II, acute physiology and chronic health evaluation
physiology score II; CT, computed tomography; MR, magnetic resonance.a close relative and the patient’s private practitioner, al-
ternatively the Medical Health Office.
The consent of a relative relies on the patient’s
presumed attitude to participation in clinical trials. The
connection between the relative and the patient will ap-
pear in the surrogate consent form. Like the patient, the
relative is also given time to make the decision of up to
several hours.
If a patient or the relatives for any reason no longer
wish to participate in the trial, they will be asked for per-
mission to use the already obtained data, to obtain data
from electronic patient files for the rest of the trial period,
and to invite the patient to the 90-day follow-up (the latter
only applies to patients in Kolding).
Data collection
Table 1 shows the types of data and the time the data will
be collected. If not otherwise stated, data originate from
medical records included in the Critical Information Sys-
tem (CIS) or other patient files or observational cards.
Data management
An eCRF for NONSEDA trial in Open Clinica is devel-
















II; SOFA, sequential organ failure assessment; SAPS II, simplified acute
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cess to the eCRF will be possible around the clock every
day where data can be entered continuously for all the
randomised patients.
The coordinating investigator will have access to
monitor the data input from all the participating centres.
If the entry is partially or completely missing or seems
flawed on one or more randomised patients, the coord-
inator will have the opportunity to contact the primary
investigator on the site in order to correct or comple-
ment data inputs to optimize the quality of the data.
Statistics
Sample size estimation
In the single-centre study from Odense University Hos-
pital, the mortality during hospitalization in the intention-
to-treat analysis was 29% in the non-sedated group and
39% in the sedated group, corresponding to a relative risk
reduction of 25% in hospital mortality [13].
In other studies and meta-analyses, the 90-day mor-
tality of the corresponding populations of mechanically
ventilated patients seems to be approximately 40%
[21,22]. It is therefore estimated, with a chosen max-
imal risk of type I error of 5% and risk of type II error
of 20% (power = 80%) that 350 patients shall be rando-
mised to each of the intervention groups, 700 patients
in total, to show or reject a relative mortality reduction
of 25%, absolute risk reduction of 10% corresponding
to numbers needed to treat of 10. This sample size cal-
culation has been made using the power and sample
size program PS [23].
Interim analysis
Study monitoring and interim analyses will be made by
an independent DMSC. The DMSC has access to the data
and will conduct their evaluation on the basis of these,
when interim analysis is conducted.
The DSMC consists of a statistician and two senior
doctors with extensive experience in intensive care
medicine.
An interim analysis from the DMSC will be carried
out when approximately 350 patients have been in-
cluded. The committee will recommend to stop the trial
if one of the groups show excess mortality or increased
frequency of SAEs, corresponding to a P value at the in-
terim analysis at 0.001 [24,25], equal to Haybittle-Peto’s
rule of discontinuing and/or Lan-DeMets terminating.
Statistical analysis plan
All patients are followed up for at least three months
after discharge via the eCRF, Social Security Register
(SSR) and the National Patient Register (NPR). Missing
data will be handled in accordance with multiple imput-
ation procedures if missing data are greater than 5% andLittle’s test is statistically significant [26]. Loss to follow-
up is estimated to be minimal but all data will be ana-
lysed by intention to treat.
Primary outcome measure
All-cause mortality at 90 days after randomisation
Primary analysis. Multivariate logistic regression
analysis adjusting for stratification variables [27].
Secondary analysis. Unadjusted univariate logistic
regression.
Tertiary analysis. Multivariate logistic regression
analysis adjusting for stratification variables and other
design variables (simplified acute physiology score II
(SAPS II) score, sequential organ failure assessment
(SOFA) score, +/− shock at randomization, +/− chronic
kidney disease, +/− chronic obstructive pulmonary
disease (COPD), +/− daily benzodiazepine treatment
prior to randomisation).
The secondary outcome measures:
1) Survival data will be analysed according to the
following three analyses:
Primary analysis: Cox-regression analysis adjusted
for stratification variables given that proportional
hazards are fulfilled, evaluated and judged by
inspection of Log(−Log) and that these cumulative
hazard curves are parallel for the intervention
groups.
Secondary analysis: unadjusted Cox-regression
analysis, given that proportional hazard are
fulfilled, evaluated and judged by inspection of
Log(−Log) and that these cumulative hazard
curves are parallel for the intervention groups,
and illustrated with Kaplan-Meier curves.
Tertiary analysis: Cox-regression analysis adjusted
for the above-mentioned stratification variables
and other design variables given that proportional
hazard are fulfilled, evaluated by inspection of
Log(−Log) and cumulative hazard curves by
intervention group.
2) Dichotomous outcomes will be analysed using
logistic regression (see the analysis plan for the
primary outcome).
3) Continuous outcomes will be compared between
the two intervention groups using the univariate
general linear model. If the model assumptions
cannot be fulfilled with reasonable approximation,
a non-parametric test will be used (Mann-Whitney).
4) Count data will be analysed using van Elteren test
(a stratified version of the nonparametric Wilcoxon
rank-sum test) adjusting for site. Bootstrapping will
be used to obtain a non-parametric estimate of the
confidence interval of the intervention effect.
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significant, as the risk of statistical multiplicity in the as-
sessment of the secondary endpoints will be evaluated
[28]. Statistical analysis of the data will be done using
SPSS 19 (IBM Corp, Armonk, NY, USA) and STATA 13
(StatCorp, College Station, TX, USA).
A detailed plan of analysis will be prepared before the
mid-term interim analysis.Discussion
The trial investigates the potential benefit of non-sedation
on clinically relevant endpoints. If a beneficial effect is
shown, this would have a large impact on future treatment
of mechanically ventilated critically ill patients.Trial status
Inclusion has started: 9 January 2014. Inclusion of patients
is scheduled for completion 1 January 2017. Articles and
PhD theses to be written and completed between 1 January
2017 and 1 June 2018. At present (July 2014) 55 patients
have been included in the study.Additional files
Additional file 1: World Health Organization Trial registration.
Data set.
Additional file 2: Protocol revision chronology.
Additional file 3: Organisational structure and responsibilities.Abbreviations
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